| Literature DB >> 29636851 |
Piotr Żukowski1, Mateusz Maciejczyk2, Jan Matczuk3, Krzysztof Kurek4, Danuta Waszkiel5, Małgorzata Żendzian-Piotrowska6, Anna Zalewska5.
Abstract
Oxidative stress plays a crucial role in the salivary gland dysfunction in insulin resistance (IR). It is not surprising that new substances are constantly being sought that will protect against the harmful effects of IR in the oral cavity environment. The purpose of this study was to evaluate the effect of N-acetylcysteine (NAC) on oxidative stress and secretory function of salivary glands in a rat model of insulin resistance. Rats were divided into 4 groups: C-normal diet, C + NAC-normal diet + NAC, HFD-high-fat diet, and HFD + NAC. We have demonstrated that NAC elevated enzymatic (superoxide dismutase, catalase, and peroxidase) and nonenzymatic antioxidants (reduced glutathione (GSH) and total antioxidant capacity (TAS)) in the parotid glands of HFD + NAC rats, while in the submandibular glands increased only GSH and TAS levels. NAC protects against oxidative damage only in the parotid glands and increased stimulated salivary secretion; however, it does not increase the protein secretion in the both salivary glands. Summarizing, NAC supplementation prevents the decrease of stimulated saliva secretion, seen in the HFD rats affected. NAC improves the antioxidative capacity of the both glands and protects against oxidative damage to the parotid glands of IR rats.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29636851 PMCID: PMC5831706 DOI: 10.1155/2018/6581970
Source DB: PubMed Journal: Oxid Med Cell Longev ISSN: 1942-0994 Impact factor: 6.543
Effect of NAC supplementation on body weight, fasting plasma glucose, insulin concentration HOMA-IR, food intake, unstimulated and stimulated saliva secretion, protein concentration, and salivary gland weight.
| C ( | C + NAC ( | HFD ( | HFD + NAC ( | |
|---|---|---|---|---|
| Final body weight (g) | 282 (260–298) | 286 (261–319) | 345 (326–364)∗∗ | 305 (250–304)∗ |
| Glucose (mg/dL) | 89 (86–93) | 95 (92–97) | 145 (130–161)∗∗ | 95 (87–99)∗ |
| Insulin (mIU/mL) | 79.70 (29.3–92.36) | 80.48 (42.22–96.96) | 166.42 (158.2–176.88)∗∗ | 61.25 (39.55–81.18)∗ |
| HOMA-IR | 3.64 (1.87–6.15) | 5.67 (2.45–6.25) | 19.60 (15.45–21.05)∗∗ | 4.33 (2.54–5.10)∗ |
| Food intake (mg/day/rat) | 17.68 (16.43–18.45) | 16.92 (15.98–19.23) | 11.82 (10.01–13.63)∗∗ | 12.25 (10.21–13.89)∗∗ |
| Energy from chow (MJ/day/rat) | 0.16 (0.15–0.18) | 0.15 (0.14–0.19) | 0.26 (0.22–0.29)∗∗ | 0.27 (0.22–0.30)∗∗ |
| NS ( | 0.43 (0.41–0.58) | 0.43 (0.40–0.51) | 0.40 (0.25–0.55) | 0.46 (0.30–0.50) |
| SS ( | 109.67 (104.58–121.37) | 91.84 (82.20–102.8) | 68.60 (56.38–70.40)∗∗ | 115.25 (96.67–152.63)∗∗ |
| Parotid weight (mg) | 76.22 (74.10–79.90) | 79.52 (72.90–87.60) | 99.46 (91.00–112.10)∗∗ | 92.55 (81.10–112.20)∗∗ |
| Submandibular weight (mg) | 211.64 (184.10–240.20) | 208.52 (192.60–222.90) | 250.04 (216.40–273.00) | 264.38 (221.90–304.20) |
C: control rats; C + NAC: control rats + N-acetylcysteine; HFD: high-fat fed rats; HFD + NAC: high-fat fed rats + N-acetylcysteine; HOMA-IR: homeostasis model assessment of insulin resistance; NS: nonstimulated saliva secretion; SS: stimulated saliva secretion: M (min–max): median (minimum–maximum). ∗p < 0.05 HFD and HFD + NAC; ∗∗p < 0.05 HFD and C; HFD + NAC and C.
Effect of NAC supplementation on plasma SOD, CAT, and GPx activities and GSH, TAS, TOS, OSI, 8-OHdG, AOPP, 4-HNE protein adduct, AGE, and total protein concentrations.
| Plasma | C | C + NAC | HFD | HFD + NAC |
|---|---|---|---|---|
| SOD (mU/mg of protein) | 0.76 (0.65–0.88) | 0.32 (0.20–0.55)∗∗ | 0.27 (0.22–0.33)∗∗ | 0.59 (0.48–0.73)∗ |
| CAT (nmol H2O2/min/mg of protein) | 1.53 (1.00–1.78) | 0.78 (0.47–1.28) | 0.73 (0.61–0.96)∗∗ | 0.66 (0.43–0.77)∗∗ |
| GPx ( | 32.85 (17.65–39.99) | 27.39 (18.25–36.32) | 34.45 (24.97–50.43) | 46.88 (33.14–53.10) |
| GSH (ng/mg of protein) | 0.72 (0.55–0.92) | 0.67 (0.46–0.94) | 0.28 (0.18–0.47)∗∗ | 0.91 (0.84–1.05)∗ |
| TAS ( | 0.62 (0.56–0.65) | 0.42 (0.35–0.53)∗∗ | 0.38 (0.34–0.41)∗∗ | 0.48 (0.38–0.58) |
| TOS ( | 1.45 (0.77–1.86) | 2.64 (1.04–4.16) | 3.52 (2.95–4.24)∗∗ | 2.08 (0.92–3.32) |
| OSI | 227.85 (122.68–296.46) | 604.77 (286.40–901.52) | 927.7 (781.51–1211.9)∗∗ | 446.87 (177.89–726.32)∗ |
| 8-OHdG (pg/mg of protein) | 0.02 (0.01–0.04) | 0.19 (0.01–0.44) | 0.12 (0.02–0.21) | 0.18 (0.02–0.34) |
| AOPP (nmol/mg of protein) | 1.55 (1.13–1.81) | 2.67 (1.59–5.36) | 3.81 (2.85–4.61)∗∗ | 2.24 (1.54–2.57) |
| 4-HNE protein adduct ( | 30.42 (14.33–50.44) | 36.29 (24.47–53.98) | 70.47 (66.52–78.64)∗∗ | 19.24 (2.46–42.48)∗ |
| AGE (fluorescence/mg of protein) | 0.89 (0.76–0.98) | 1.37 (0.86–2.61) | 1.41 (1.04–1.94) | 1.16 (0.73–1.15) |
| Protein ( | 4551 (4103–4964) | 4423.9 (3588.6–5027.4) | 4271.0 (3471.3–4848.8) | 3886.2 (3432.0–5027.4) |
C: control rats; C + NAC: control rats + N-acetylcysteine; HFD: high-fat fed rats; HFD + NAC: high-fat fed rats + N-acetylcysteine; M: median: min: minimum; max: maximum; SOD: superoxide dismutase; CAT: catalase, GPx: glutathione peroxidase; GSH: reduced glutathione; TAS: total antioxidant status; TOS: total oxidant status; OSI: oxidative status index; 8-OHdG: 8-hydroxy-d-guanosine; AOPP: advanced oxidation protein products; 4-HNE protein adduct: 4 hydroxynonenal protein adduct; AGE: advanced glycation end products. ∗p < 0.05 HFD and HFD + NAC; ∗∗p < 0.05 C + NAC and C; HFD and C; HFD + NAC and C.
Effect of NAC supplementation on parotid glands SOD, CAT, and Px activities and GSH, TAS, TOS, OSI, 8-OHdG, AOPP, 4-HNE protein adduct, AGE, and total protein concentrations.
| Parotid glands | C | C + NAC | HFD | HFD + NAC |
|---|---|---|---|---|
| SOD (mU/mg of protein) | 0.62 (0.44–1.17) | 0.37 (0.33–0.42) | 0.29 (0.18–0.31)∗∗ | 0.57 (0.36–0.68)∗ |
| CAT (nmol H2O2/min/mg of protein) | 0.81 (0.59–0.97) | 0.84 (0.53–1.13) | 0.76 (0.09–1.09) | 1.26 (1.2–1.74)∗,∗∗ |
| Px ( | 55.7 (51.4–59.5) | 34.5 (25.5–60.6) | 37.4 (33.5–39.6)∗∗ | 52.9 (46.7–55.9)∗ |
| GSH (ng/mg of protein) | 0.94 (0.95–0.99) | 1.12 (0.70–1.55) | 0.73 (0.52–0.88)∗∗ | 1.18 (0.86–1.73)∗ |
| TAS ( | 0.67 (0.65–0.99) | 0.65 (0.53–0.82) | 0.32 (0.27–0.49)∗∗ | 0.92 (0.66–1.13)∗ |
| TOS ( | 1.30 (0.76–1.78) | 0.69 (0.36–0.98) | 2.24 (1.98–2.54)∗∗ | 1.25 (0.47–1.67)∗ |
| OSI | 192.9 (116.0–258.0) | 114.3 (44.0–172.0) | 536.9 (403.6–620.6)∗∗ | 165.8 (68.0–366.3)∗ |
| 8-OHdG (pg/mg of protein) | 1.47 (1.31–1.58) | 1.19 (0.89–1.39) | 1.91 (1.80–1.99)∗∗ | 1.53 (1.16–1.57)∗ |
| AOPP (nmol/mg of protein) | 10.0 (6.2–12.4) | 9.6 (1.7–12.8) | 23.4 (18.0–34.1)∗∗ | 11.64 (7.90–14.6)∗ |
| 4-HNE protein adduct ( | 10.70 (2.16–18.9) | 5.70 (1.59–10.54) | 50.7 (30.4–57.3)∗∗ | 1.78 (0.34–2.91)∗ |
| AGE (fluorescence/mg of protein) | 0.41 (0.36–0.46) | 0.38 (0.28–0.53) | 0.41 (0.35–0.52) | 0.48 (0.44–0.52) |
| Protein ( | 4419 (4054–4889) | 3654 (3348–4031) | 3324 (3000–3828)∗∗ | 3292.52 (2930.30–3457.30)∗∗ |
C: control rats; C + NAC: control rats + N-acetylcysteine; HFD: high-fat fed rats; HFD + NAC: high-fat fed rats + N-acetylcysteine; M: median; min: minimum; max: maximum; SOD: superoxide dismutase; CAT: catalase; Px: peroxidase; GSH: reduced glutathione; TAS: total antioxidant status; TOS: total oxidant status; OSI: oxidative status index; 8-OHdG: 8-hydroxy-d-guanosine; AOPP: advanced oxidation protein products; 4-HNE protein adduct: 4 hydroxynonenal protein adduct; AGE: advanced glycation end products. ∗p < 0.05 HFD and HFD + NAC; ∗∗p < 0.05 C + NAC and C; HFD and C; HFD + NAC and C.
Effect of NAC supplementation on submandibular glands SOD, CAT, and Px activities and GSH, TAS, TOS, OSI, 8-OHdG, AOPP, 4-HNE protein adduct, AGE, and total protein concentrations.
| Submandibular glands | C | C + NAC | HFD | HFD + NAC |
|---|---|---|---|---|
| SOD (mU/mg of protein) | 0.33 (0.12–0.48) | 0.36 (0.33–0.41) | 0.33 (0.23–0.39) | 0.37 (0.24–0.49) |
| CAT (nmol H2O2/min/mg of protein) | 1.18 (0.98–1.36) | 1.02 (0.76–1.27) | 1.1 (0.8–1.4) | 1.34 (1.11–1.65) |
| Px ( | 48.36 (44.53–53.91) | 38.8 (28.1–56.1) | 32.76 (22.11–40.04)∗∗ | 31.78 (29.24–35.30)∗∗ |
| GSH (ng/mg of protein) | 1.09 (0.95–1.18) | 1.31 (1.05–1.64) | 0.56 (0.16–0.76)∗∗ | 0.95 (0.83–1.21)∗ |
| TAS ( | 0.56 (0.43–0.73) | 0.63 (0.44–0.81) | 0.35 (0.22–0.46)∗∗ | 0.61 (0.55–0.78)∗ |
| TOS ( | 0.61 (0.37–0.79) | 0.58 (0.34–0.87) | 1.6 (1.4–1.9)∗∗ | 1.24 (1.05–1.35)∗,∗∗ |
| OSI | 118.47 (50.47–169.84) | 89.92 (58.09–114.92) | 471.10 (326.46–621.83)∗∗ | 187.2 (179.4–280.7)∗,∗∗ |
| 8-OHdG (pg/mg of protein) | 1.23 (1.02–1.41) | 1.29 (1.11–1.47) | 1.31 (1.01–1.87) | 1.42 (1.36–1.49) |
| AOPP (nmol/mg of protein) | 9.35 (7.90–11.01) | 9.81 (9.32–12.57) | 18.85 (17.69–23.31)∗∗ | 15.47 (12.74–16.97)∗,∗∗ |
| 4-HNE protein adduct ( | 7.29 (3.74–10.61) | 32.82 (9.99–46.88)∗∗ | 37.88 (27.41–45.84)∗∗ | 21.27 (13.24–26.02)∗,∗∗ |
| AGE (fluorescence/mg of protein) | 0.26 (0.21–0.37) | 0.5 (0.45–0.52)∗∗ | 0.41 (0.39–0.45)∗∗ | 0.32 (0.20–0.55) |
| Protein ( | 3804 (3567–3933) | 3548 (3413–3673) | 3210 (3080–3387)∗∗ | 3282 (3160–3423)∗∗ |
C: control rats; C + NAC: control rats + N-acetylcysteine; HFD: high-fat fed rats; HFD + NAC: high-fat fed rats + N-acetylcysteine; M: median; min: minimum; max: maximum; SOD: superoxide dismutase; CAT: catalase; Px: peroxidase; GSH: reduced glutathione; TAS: total antioxidant status; TOS: total oxidant status; OSI: oxidative status index; 8-OHdG: 8-hydroxy-d-guanosine; AOPP: advanced oxidation protein products; 4-HNE protein adduct: 4 hydroxynonenal protein adduct; AGE: advanced glycation end products. ∗p < 0.05 HFD and HFD + NAC; ∗∗p < 0.05 C + NAC and C; HFD and C; HFD + NAC and C.